PH sensitive biodegradable polymeric particles for drug delivery

Patent metadata

Field	Value
Publication number	US-9532956-B2
Application number	US-76234810-A
Country	US
Kind code	B2
Filing date	Apr 18, 2010
Priority date	Apr 18, 2009
Publication date	Jan 3, 2017
Grant date	Jan 3, 2017

Abstract

The present invention generally relates to polymers and particles, such as nanoparticles. The particles and polymers generally include one or more buffering components. Additionally, the particles and polymers may include two or more components that impart useful properties (functionalities). The particles and polymers, for example, may include a buffering component and a degradable component. As described herein, the particles and polymers may also include a hydrophilic component and/or a cleavable bond component. The particles and polymers described herein have been found to be particularly effective when used for delivery of one or more agents, such as one or more pharmaceutical agents. Other aspects of the invention are directed to methods of using or administering such particles or polymers, kits involving such particles or polymers, and the like. The present invention also relates to particles containing a cleavable bond component and one or more fluorescence resonance energy transfer (FRET) pairs as well as methods of detecting the cleavage of the cleavable bond component of such particles.

First claim

What is claimed is:

1. A polymeric particle formed by self-assembly of one or more copolymers consisting of a first pH sensitive covalent copolymer conjugate and optionally a second pH insensitive covalent copolymer conjugate,
wherein the first covalent copolymer conjugate has the following formula:
A 1 -B-C 1

wherein the second covalent copolymer conjugate has the following formula:
A 2 -C 2

wherein A 1 and A 2 are hydrophobic biodegradable polymers; B is a positively charged pH sensitive polymer; and C 1 and C 2 are hydrophilic polymers, and
wherein the self-assembled polymeric particle comprises a core formed of the hydrophobic biodegradable polymer, the hydrophilic polymer forms the surface of the polymeric particle, and the positively charged pH sensitive polymer is present between the core and the hydrophilic polymer surface, wherein the particle does not include a targeting ligand or moiety.

2. The particle of claim 1 , wherein A 1 is polylactic acid, polyglycolic acid or poly(lactide-co-glycolide) conjugated to B which is a polyhistidine conjugated to C 1 which is a polyethylene glycol.

3. The particle of claim 1 further comprising an agent to be delivered.

4. A composition comprising one or more of the particles of claim 1 and a pharmaceutically acceptable carrier.

5. The particle of claim 1 , wherein the positively charged pH sensitive polymer is selected from the group consisting of polyhistidine, polylysine, polyarginine, a copolymer of histidine and lysine, a copolymer of histidine and arginine, a copolymer of lysine and arginine, poly(ethylene imine), and poly(beta amino ester).

6. The particle of claim 1 , wherein the hydrophobic biodegradable polymer is selected from the group consisting of polyester, polyanhydride, poly(ortho ester), poly(caprolactone), poly(ethylene imine), poly(acrylic acid), poly(urethane), and combinations thereof.

7. The particle of claim 1 , wherein the hydrophilic polymer is a polyalkylene glycol or a polyalkylene oxide.

8. The particle of claim 1 , wherein the positively charged pH sensitive polymer is covalently conjugated to the hydrophobic biodegradable polymer, hydrophilic polymer or both via a cleavable bond selected from the group consisting of a pH-cleavable bond, a redox-active cleavable bond, and an enzymatically cleavable bond.

9. The particle of claim 8 , wherein the cleavable bond is selected from the group consisting of diorthoester, orthoester, vinylether, phosphoroamidate, hydrazone, beta-thiopropionate, low pKa polyplex, disulfide, redox-sensitive chimeric polypeptide linker, alpha-helical linker with redox sensitive motifs, alpha-helix with embedded adjacent or dispersed vicinal cysteine residues, and protease-cleavable peptide bond.

10. The particle of claim 9 , wherein the cleavable bond comprises a disulfide bond.

11. The particle of claim 9 , wherein the positively charged pH sensitive polymer is a polyhistidine, the hydrophobic polymer is polylactic-co-glycolic acid), the hydrophilic polymer is polyethylene glycol, the polyhistidine is covalently conjugated to the poly(lactic-co-glycolic acid) via an amide bond and the polyethylene glycol is covalently conjugated to the polyhistidine via a disulfide bond.

12. The particle of claim 1 , wherein the zeta potential difference of the particle at a physiological pH relative to an endosomal pH is at least 5 millivolts, or wherein the zeta potential of the particle is more positive at an endosomal pH than at a physiological pH.

13. The particle of claim 1 , wherein A 1 and A 2 are the same, C 1 and C 2 are the same, or both.

14. The particle of claim 1 , wherein A 2 is poly(lactic-co-glycolic acid) and C 2 is polyethylene glycol.

15. A polymeric particle formed by self-assembly of one or more copolymers consisting of a first pH sensitive covalent copolymer conjugate and a second pH insensitive covalent copolymer conjugate,
wherein the first covalent copolymer conjugate has the following formula:
A 1 -B-C 1

wherein the second covalent copolymer conjugate has the following formula:
A 2 -C 2

wherein A 1 and A 2 are hydrophobic biodegradable polymers; B is a positively charged pH sensitive polymer; and C 1 and C 2 are hydrophilic polymers, and
wherein the self-assembled polymeric particle comprises a core formed of the hydrophobic biodegradable polymer, the hydrophilic polymer forms the surface of the polymeric particle, and the positively charged pH sensitive polymer is present between the core and the hydrophilic polymer surface, wherein the particle does not include a targeting ligand or moiety.

16. The particle of claim 1 having encapsulated therein one or more pharmaceutical agents selected from the group consisting of antiinfectives, antineoplastic or cytostatic agents and anti-inflammatory agents.

17. The particle of claim 11 , wherein A 2 is polylactic acid, polyglycolic acid or poly(lactide-co-glycolide) and C 2 is polyalkylene oxide.

18. The particle of claim 17 , wherein the polyalkylene oxide is polyethylene glycol.

19. A method, comprising:
administering the composition of claim 4 to a subject.

Assignees

• Radovic-Moreno Aleksandar Filip
• Gao Weiwei
• Swami Archana
• Golomb Gershon
• Langer Robert S
• Farokhzad Omid C
• Massachusetts Inst Technology
• Brigham & Womens Hospital Inc

Inventors

• Radovic-Moreno Aleksandar Filip
• Gao Weiwei
• Swami Archana
• Golomb Gershon
• Langer Robert S
• Farokhzad Omid C

Classifications

• A61K9/51 Primary

  Nanocapsules; {Nanoparticles; (nanotubes A61K9/0092; polymeric micelles A61K9/1075; polymersomes A61K9/1273; pure drug nanoparticles A61K9/14; drug nanoparticles with adsorbed surface modifiers A61K9/141; conjugates, e.g. between drug and non-active nanoparticles, A61K47/50; preparations for in vivo diagnosis A61K49/00; with radioactive substances A61K51/00)} · CPC title

• C12N15/115

  Aptamers, i.e. nucleic acids binding a target molecule specifically and with high affinity without hybridising therewith {; Nucleic acids binding to non-nucleic acids, e.g. aptamers} · CPC title

• C12N2310/16

  Aptamers · CPC title

• A61K48/0008

  characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition · CPC title

• C12N2320/32

  Special delivery means, e.g. tissue-specific · CPC title